Search
Use the filters to narrow by type of content
Looking for a Publication? Search the bibliography for: updates events www Viqtory com
HTA Processes for Medical Technologies Across the World – Are All Hurdles the Same? Liesl Gildea, MSc Associate Director, Market Access and Outcomes Strategy RTI Health Solutions HTA processes for medical technologies across the world – are all hurdles …
A Cost-Effectiveness Analysis Using Real-World Data William Herring, PhD Director, Health Economics RTI Health Solutions A Cost-Effectiveness Analysis Using Real-World Data from the MSBase Registry: Comparing Natalizumab to Fingolimod in Patients with …
Joan Fortuny Pharmacoepidemiology and Risk Management Hematology Ophthalmology Oncology CNS/Neurology Barcelona, Spain PhD, Pharmacology (Pharmacoepidemiology) MD, School of Medicine Autonomous University of Barcelona, Barcelona, Spain Specialist in …
Multi-Criteria Decision Analysis Most drug development and commercialization choices are complex. When you have multiple factors influencing a decision and you have to consider tradeoffs, you need a tool that can help you compare, prioritize and select …
Equity, Diversity, Inclusion, and Belonging in Patient Centered Drug Development Chad Downey, BS Associate Director, Project and Proposal Office RTI Health Solutions Advancing equity, diversity, inclusion, and belonging in patient centered drug …
Biostatistics Data Analysis and Visualization Can Help Strengthen Your Pharma or Medical Technology Product Development The value of your data may be greater than you think. Unexplored trial or observational data may contain a goldmine of information to …
Trends in the Inclusion of Patient Reported Outcomes in Oncology Clinical Trials Margaret Mordin, MS Vice President, Market Access and Outcomes Strategy RTI Health Solutions Trends in the inclusion of patient reported outcomes in oncology clinical trials: …
Gene Therapy Keep your gene therapy development on track The paradigm of regenerative medicine development is changing. Expedited regulatory approvals can help developers, but only if they are timely with strategic planning and fully versed in the latest …
… Dr. Goyal also has experience in assessing adverse events, disease progression, medication adherence, drug …
How are United States ICER'S Evidence Ratings Determined? You can read the related research here: How are United States ICER'S evidence ratings determined?: A systematic review of ICER'S evidence ratings in evidence reports for new drugs in 2020 and 2021. …